CN1313113C - 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method - Google Patents
'Wudan Xinggan' granular for treating fatty liver, and its prepn. method Download PDFInfo
- Publication number
- CN1313113C CN1313113C CNB2005100440695A CN200510044069A CN1313113C CN 1313113 C CN1313113 C CN 1313113C CN B2005100440695 A CNB2005100440695 A CN B2005100440695A CN 200510044069 A CN200510044069 A CN 200510044069A CN 1313113 C CN1313113 C CN 1313113C
- Authority
- CN
- China
- Prior art keywords
- wudan
- xinggan
- granule
- weight
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 12
- 208000004930 Fatty Liver Diseases 0.000 title claims description 11
- 206010019708 Hepatic steatosis Diseases 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 5
- 239000008187 granular material Substances 0.000 claims abstract description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 11
- 239000004375 Dextrin Substances 0.000 claims abstract description 6
- 229920001353 Dextrin Polymers 0.000 claims abstract description 6
- 235000019425 dextrin Nutrition 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 11
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 240000001341 Reynoutria japonica Species 0.000 abstract 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 235000005412 red sage Nutrition 0.000 abstract 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 abstract 1
- 238000010960 commercial process Methods 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 33
- 210000002966 serum Anatomy 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003119 painkilling effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Abstract
The present invention relates to a Wudan Xinggan granule for treating hyperlipemia blood type fatty liver or alcoholic fatty liver diseases and a preparation method of the Wudan Xinggan granule. The medicine of the present invention is prepared from the following active components extracted from raw materials according to weight portions of 600 to 700 portions of red sage roots, 450 to 550 portions of prepared fleece flower roots and 250 to 350 portions of haws. The preparation method of the Wudan Xinggan granule comprises the following steps: alcohol extraction and water extraction of the red sage roots respectively, alcohol extraction of the prepared fleece flower roots and the haws, extract combination, dextrin and rebaudiose addition and packaging. The Wudan Xinggan granule of the present invention has the advantages of simple prescription, good curative effect, small toxic and side effects, simple preparation process and little effective component loss, and the present invention is suitable for commercial process.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation for the treatment of fatty liver and preparation method thereof, particularly a kind of Wudan Xinggan granule for the treatment of hepar adiposum of hyperlipoidemia type or alcohol fatty hepatopathy and preparation method thereof.
Background technology:
Along with the raising of people's living standard, the sickness rate of hepar adiposum of hyperlipoidemia type or alcohol fatty hepatopathy is more and more higher.At present, still there is not ideal specific treatment medicine for fatty liver both at home and abroad.Herb Gynostemmae Pentaphylli assembly commonly used clinically, Max EPA, clofibrate, Leping fat etc., big multiaction relaxes, and curative effect is not remarkable, and the medicine life-time service that has has damage to liver, should not be used for the treatment of fatty liver, and the medicine that has also can produce toxic and side effects.
The compound Chinese medicinal preparation of Chinese patent CN1343514, treatment fatty liver, prescription is chitosan, Radix Polygoni Multiflori Preparata, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Rhizoma Alismatis and Semen Cassiae, preparation method is that water extract-alcohol precipitation, spray drying method are made.But its medicament composing prescription is more, the preparation method complexity, and effective ingredient is big, and certain toxic and side effects is arranged.
Summary of the invention
The object of the present invention is to provide that a kind of prescription is simple, the Wudan Xinggan granule of good effect, treatment fatty liver that toxic and side effects is little.
Another object of the present invention is to provide above-mentioned particulate preparation method, this method has that technology is simple, loss of effective components is little.
The present invention relates to a kind of Wudan Xinggan granule for the treatment of fatty liver, extract active component by the raw material of following weight parts and make:
600～700 parts of Radix Salviae Miltiorrhizaes
450～550 parts of Radix Polygoni Multiflori Preparata
250～350 parts of Fructus Crataegis.
Wudan Xinggan granule of the present invention, optimum weight part of described raw material is:
666.7 parts of Radix Salviae Miltiorrhizaes
500 parts of Radix Polygoni Multiflori Preparata
333.3 parts of Fructus Crataegis.
The particulate preparation method of above-mentioned Wudan Xinggan, according to the following steps,
A: Radix Salviae Miltiorrhizae adds 10 times of weight, 8 times of weight, 80% alcohol heating reflux and extracts secondary, and the time was respectively 2 hours, 1 hour, and merge extractive liquid, filters, and being concentrated into 60～75 ℃ of relative densities is 1.20～1.22 clear paste, standby;
B: the medicinal residues after the Radix Salviae Miltiorrhizae alcohol extraction add 8 times of weight, 6 times of weight water, decocted respectively 2 hours, 1 hour, and merging filtrate, being concentrated into 60～75 ℃ of relative densities is 1.20～1.22 clear paste, standby;
C: Radix Polygoni Multiflori Preparata, Fructus Crataegi add 10 times of weight, 8 times of weight, 60% alcohol heating reflux and extract secondary, and 1.5 hours, 1 hour respectively time, merge extractive liquid, filters, and being concentrated into 60～75 ℃ of relative densities is 1.20～1.22 clear paste, standby;
D: above-mentioned clear paste merges, and makes granule with dextrin, steviosin, and packing promptly.
The best proportioning that the particulate preparation method of above-mentioned Wudan Xinggan, steviosin account for the granule gross weight is 0.5%.
Every bag contains danshensu (C
9H
10O
5) must not be less than 20.0mg.
This prescription derive from the lifetime professor of Shandong Traditional Chinese Medicine University, national distinguished veteran doctors of TCM Mr. Zhang Zhenyu long-term treatment hepar adiposum of hyperlipoidemia type or alcohol fatty hepatopathy through proved recipe.The Zhang Zhenyu professor forms we according to the ancient prescription sanction, cures mainly because the surfeit crust is sweet, and insobriety causes spleen injury, dysfunction of the spleen in transportation, poly-humidogene heat, damp-heat accumulation, blood stasis resistance network, disharmony between QI and blood and cause hypochondriac pain, knot hinders and form alcoholophilia in abdomen even QI and blood expectorant is fought, and the wine distension takes place then; Dysfunction of the spleen in transportation, the retardance of the expectorant stasis of blood, hematogenous blockage etc.We are at the main syndrome etiology and pathogenesis, and Radix Salviae Miltiorrhizae is a monarch drug in the side, stasis-dispelling and pain-killing, and promoting blood flow to regulate menstruation, relieving restlessness clears away heart-fire; Ministerial drug Radix Polygoni Multiflori Preparata replenishing blood and nourishing liver, beneficial essence is reinforced the kidney; Adjuvant drug hawthorn digesting eliminate indigestion, promoting the circulation of QI to relieve pain, blood circulation promoting and blood stasis dispelling.Take an overall view of full side, at the main syndrome etiology and pathogenesis, with stasis-dispelling and pain-killing, fat-reducing liver-protecting is main, assistant is with nourishing the liver and kidney, and blood-activating and qi-promoting is conceived to remove the cause of disease, corrects pathogenesis, it is intricately woven together that choosing side sends medicine and its etiology and pathogenesis and site of pathological change, thus the sick damp-heat accumulation of energy mainly treating fatty liver, blood stasis resistance network card.Because of reasonable recipe, method of treatment degree of having suits pathogenesis, so clinical efficacy is reliable and stable.
Wudan Xinggan granule of the present invention has that prescription is simple, a good effect, advantage that toxic and side effects is little.
Preparation method of the present invention have preparation technology simple, be suitable for suitability for industrialized production, advantage that loss of effective components is little.
The specific embodiment
Embodiment 1:
A: get Radix Salviae Miltiorrhizae 600g and add 6000mL, 4800mL80% alcohol heating reflux extraction secondary, 2 hours time, 1 hour, merge extractive liquid, filters, and is concentrated into relative density and is the about 180g of clear paste of 1.20～1.22 (60～75 ℃), and is standby:
B: medicinal residues add water 4800mL, 3600mL, decoct 2 hours, 1 hour, and merging filtrate is concentrated into relative density and is the about 210g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
C: get Radix Polygoni Multiflori Preparata 450g, Fructus Crataegi 25g and add 7000mL, 5600mL60% alcohol heating reflux extraction secondary, 1.5 hours time, 1 hour, merge extractive liquid, filters, and is concentrated into relative density and is the about 72g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
D: above-mentioned clear paste merges, and, steviosin 5g an amount of with dextrin makes the 100g granule, and packing promptly.
Usage and consumption: oral, three times on the one, each 6g.
Embodiment 2:
A: Radix Salviae Miltiorrhizae 700g adds 7000mL, the 5600mL80% alcohol heating reflux extracts secondary, and 2 hours time, 1 hour, merge extractive liquid, filters, and is concentrated into relative density and is the about 210g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
B: medicinal residues add water 5600mL, 4200mL doubly, decoct 2 hours, 1 hour, and merging filtrate is concentrated into relative density and is the about 245g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
C: Radix Polygoni Multiflori Preparata 550g, Fructus Crataegi 350g add 9000ml, the 720mL60% alcohol heating reflux extracts secondary, and 1.5 hours time, 1 hour, merge extractive liquid, filters, and is concentrated into relative density and is the about 230g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
D: above-mentioned clear paste merges, and, steviosin 5g an amount of with dextrin makes the 1000g granule, and packing promptly.
Usage and consumption: oral, three times on the one, each 6g.
Embodiment 3:
A: Radix Salviae Miltiorrhizae 666.7g adds 6667mL, the 5333mL80% alcohol heating reflux extracts secondary, and 2 hours time, 1 hour, merge extractive liquid, filters, and is concentrated into relative density and is the about 200g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
B: medicinal residues add water 5333mL, 4000mL, decoct 2 hours, 1 hour, and merging filtrate is concentrated into relative density and is the about 233g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
C: Radix Polygoni Multiflori Preparata 500g, Fructus Crataegi 333.3g add 8333mL, the 6666mL60% alcohol heating reflux extracts secondary, and 1.5 hours time, 1 hour, merge extractive liquid, filters, and is concentrated into relative density and is the about 225g of clear paste of 1.20～1.22 (60～75 ℃), and is standby;
D: above-mentioned clear paste merges, and, steviosin 5g an amount of with dextrin makes the 1000g granule, and packing promptly.
Usage and consumption: oral, three times on the one, each 6g.
The invention described above obtains the Wudan Xinggan granule except reaching the general prescription of granule, and this product this product contains danshensu (C for every bag
9H
10O
5) must not be less than 20.0mg.
Stability observing: 3 months reserved sample observing methods are measured the preliminarily stabilised of this preparation, and the result shows that this preparation was stable in 3 months, and its long-time stability await further observation.
With the Wudan Xinggan granule of embodiment 1, carry out following main pharmacodynamics experiment below.The Wudan Xinggan granule is divided into large, medium and small dosage and experimentizes, and the large, medium and small three kinds of dosage of mice are respectively 9.00g/kg, 4.5g/kg, 2.25g/kg, and the large, medium and small three kinds of dosage of rat are respectively 4.50g/kg, 2.25g/kg, 1.13g/kg.
1 Wudan Xinggan granule is to the influence of high fat animal model blood fat, liver fat
The large, medium and small dosage of Wudan Xinggan granule can significantly reduce high fat modeling mice serum TC content; Wudan Xinggan granule low dose can significantly improve modeling mice serum HDL-C content; Dosage can significantly reduce modeling mice serum LDL-C content in the Wudan Xinggan granule.
The large, medium and small dosage of Wudan Xinggan granule can significantly reduce high fat modeling Serum TC content; The big or middle dosage of Wudan Xinggan granule can significantly improve modeling rat blood serum HDL-C content; Wudan Xinggan granule heavy dose can significantly reduce modeling rats'liver TC content; The large, medium and small dosage of Wudan Xinggan granule can significantly reduce modeling rats'liver TG content
2 Wudan Xinggan granules are to the influence of hyperlipidemia type fatty liver rat
Wudan Xinggan granule low dose can reduce modeling rats'liver index significantly; The big or middle dosage of Wudan Xinggan granule can significantly reduce high fat modeling Serum TC content; Dosage can significantly reduce modeling rat blood serum HDL-C content, rising HDL-C/TC in the Wudan Xinggan granule; Dosage can significantly reduce high fat modeling rat blood serum LDL-C content in the Wudan Xinggan granule; Dosage can significantly reduce modeling rats'liver TC content, liver TG content in the Wudan Xinggan granule.
3 Wudan Xinggan granules are to the influence of chmice acute hepatic injury
The large, medium and small dosage of Wudan Xinggan granule is to CCL
4Cause the rising of mouse liver injury Serum ALT remarkable reduction effect is arranged; Dosage is to CCL in the Wudan Xinggan granule
4Modeling mice serum AST raises remarkable reduction effect.
The Wudan Xinggan granule causes the rising of mouse liver injury Serum ALT to ethanol the reduction effect, and does not have the significance meaning with ordinary water group difference; The big or middle dosage of Wudan Xinggan granule can significantly reduce ethanol modeling mice serum AST.
4 Wudan Xinggan granules are to the influence of rat acute alcoholic liver injury
Dosage raises to modeling rat blood serum ALT in the Wudan Xinggan granule remarkable reduction effect; The Wudan Xinggan granule raises to modeling rat blood serum AST the reduction effect; Dosage reduces modeling rat blood serum GSH-PX in the Wudan Xinggan granule significant rising effect; The Wudan Xinggan granule raises to modeling liver tissues of rats MDA greatly remarkable reduction effect; The large, medium and small dosage of Wudan Xinggan granule can significantly improve modeling liver tissues of rats GSH-PX and SOD content.
5 Wudan Xinggan granules are to the influence of rat long term alcohol liver damage
The large and small dosage of Wudan Xinggan granule can significantly reduce the liver index of ethanol hepatopathy modeling rat; Rising has the reduction effect to modeling rat blood serum ALT, but does not have the significance meaning; Wudan Xinggan granule heavy dose can significantly reduce modeling rat blood serum AST, significantly reduces modeling rat blood serum MDA; Wudan Xinggan granule low dose can significantly raise modeling rat blood serum GSH-PX and SOD; The Wudan Xinggan granule raises to modeling liver tissues of rats MDA the reduction effect, but does not have the significance meaning; The large, medium and small dosage of Wudan Xinggan granule all can significantly improve modeling liver tissues of rats GSH-PX and SOD content.
6 Wudan Xinggan granules to the hyperlipidemia model rat in the body, the influence that forms of external thrombus
The large, medium and small dosage group of Wudan Xinggan granule can significantly reduce the formation of hyperlipidemia model rat thrombus in vivo.
The dosage group can significantly reduce the weight in wet base of rats in vitro thrombosis in the Wudan Xinggan granule.
7 Wudan Xinggan granules are to the influence of hyperlipidemia model rat platelet aggregation
The big or middle dosage group of Wudan Xinggan granule can significantly reduce the platelet aggregation rate of rat.
8 Wudan Xinggan granules are to the influence of hyperlipidemia model hemorheology of rat
The big or middle dosage group of Wudan Xinggan granule can significantly reduce whole blood viscosity, the whole blood reduced viscosity in the hyperlipidemia model rat plasma, and middle dosage group can significantly reduce rat model ESR equation K value.
9 Wudan Xinggan granule immunizations influence experimental study
Wudan Xinggan granule heavy dose, low dose can obviously improve carbon clearance index K value, and heavy dose of raising of Wudan Xinggan granule proofreaied and correct carbon clearance index α value.
Wudan Xinggan granule heavy dose can obviously improve the mice serum hemolysin.
Toxicology test
1. acute toxicity test
The Wudan Xinggan granule can not surveyed LD by the prerun test
50, thereby carry out the mice maximum dosage-feeding and measure, recording mice, to irritate the stomach maximum dosage-feeding in one day be 279.0gkg
-1(crude drug/body weight), 620 times of the clinical application amount that is equivalent to be grown up are not seen the overt toxicity reaction.The result shows that mice was irritated the particulate safe dose of stomach Wudan Xinggan on the 1st at 279.0gkg
-1More than.
2. long term toxicity test
This experimental observation rat continuous irrigation stomach give the toxic reaction 24 weeks of Wudan Xinggan granule the body whole body is produced, and drug withdrawal observed for 4 weeks as convalescent period, to observe the degree of reversibility of toxic reaction.Result of the test shows: during the administration, large, medium and small dosage group rat body weight and food ration change and matched group compares there was no significant difference, hematology, blood biochemical are learned every index and are compared there was no significant difference with matched group, each organ macroscopy of large, medium and small dosage group and matched group relatively do not have significant difference, and finding is compared with matched group and also do not had significant difference under each test period of Wudan Xinggan granule heavy dose of group internal organs section mirror.Test shows that it is more than the 27.0g/kg that continuous 24 weeks of rat gavage the particulate safe dose of Wudan Xinggan.
Claims (4)
1. Wudan Xinggan granule for the treatment of fatty liver is characterized in that: extracts active component by the raw material of following weight parts and makes,
600～700 parts of Radix Salviae Miltiorrhizaes
450～550 parts of Radix Polygoni Multiflori Preparata
250～350 parts of Fructus Crataegis.
2. Wudan Xinggan granule according to claim 1 is characterized in that: the weight portion of described raw material is:
666.7 parts of Radix Salviae Miltiorrhizaes
500 parts of Radix Polygoni Multiflori Preparata
333.3 parts of Fructus Crataegis.
3. claim 1 or the particulate preparation method of 2 described Wudan Xinggans is characterized in that: according to the following steps,
A: Radix Salviae Miltiorrhizae adds 10 times of weight, 8 times of weight, 80% alcohol heating reflux and extracts secondary, and the time was respectively 2 hours, 1 hour, and merge extractive liquid, filters, and being concentrated into 60～75 ℃ of relative densities is 1.20～1.22 clear paste, standby;
B: the medicinal residues after the Radix Salviae Miltiorrhizae alcohol extraction add 8 times of weight, 6 times of weight water, decocted respectively 2 hours, 1 hour, and merging filtrate, being concentrated into 60～75 ℃ of relative densities is 1.20～1.22 clear paste, standby;
C: Radix Polygoni Multiflori Preparata, Fructus Crataegi add 10 times of weight, 8 times of weight, 60% alcohol heating reflux and extract secondary, and 1.5 hours, 1 hour respectively time, merge extractive liquid, filters, and being concentrated into 60～75 ℃ of relative densities is 1.20～1.22 clear paste, standby;
D: above-mentioned clear paste merges, and makes granule with dextrin, steviosin, and packing promptly.
4. the particulate preparation method of Wudan Xinggan according to claim 3, it is characterized in that: steviosin accounts for 0.5% of granule gross weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100440695A CN1313113C (en) | 2005-07-13 | 2005-07-13 | 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100440695A CN1313113C (en) | 2005-07-13 | 2005-07-13 | 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1724018A CN1724018A (en) | 2006-01-25 |
| CN1313113C true CN1313113C (en) | 2007-05-02 |
Family
ID=35923736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100440695A Expired - Fee Related CN1313113C (en) | 2005-07-13 | 2005-07-13 | 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1313113C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985909B (en) * | 2007-01-08 | 2010-06-16 | 江苏济川制药有限公司 | Medicine for hyperlipemia and its production process |
| CN102362903A (en) * | 2011-10-03 | 2012-02-29 | 周春根 | Traditional Chinese medicine for treating hyperlipidemia |
| CN103041002B (en) * | 2013-02-07 | 2016-04-06 | 杨波 | A kind of protecting liver and expelling toxin recovers Chinese medicine powder of liver function and preparation method thereof |
| CN104042707B (en) * | 2013-11-28 | 2016-04-13 | 天津天狮生物发展有限公司 | A kind of Chinese medicine composition and preparation method containing Radix Polygoni Multiflori extract |
| CN106310108A (en) * | 2015-06-24 | 2017-01-11 | 北大方正集团有限公司 | Medicinal composition for treating fatty liver |
| CN105412278A (en) * | 2015-12-11 | 2016-03-23 | 普洱淞茂制药股份有限公司 | Medicine composition, preparation method thereof, preparation and application |
| CN107397809A (en) * | 2017-07-14 | 2017-11-28 | 三峡大学 | The application of panax japonicus, the red sage root, hawthorn formula on the medicine for preparing treatment fatty liver disease |
| CN108310164A (en) * | 2018-05-16 | 2018-07-24 | 刘朝顺 | It is a kind of treat and prevent acute and chronic hepatitis Chinese medicine composition and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263772A (en) * | 1999-12-30 | 2000-08-23 | 鞠奎信 | Hypolipemic capsule |
| CN1524540A (en) * | 2003-02-28 | 2004-09-01 | 唐山康琳药业有限公司 | Chinese medicine preparation for treating fatty liver and its preparation method |
-
2005
- 2005-07-13 CN CNB2005100440695A patent/CN1313113C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263772A (en) * | 1999-12-30 | 2000-08-23 | 鞠奎信 | Hypolipemic capsule |
| CN1524540A (en) * | 2003-02-28 | 2004-09-01 | 唐山康琳药业有限公司 | Chinese medicine preparation for treating fatty liver and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1724018A (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1313113C (en) | 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method | |
| CN1186071C (en) | Medicines composition for treating chronic heart failure and its prepn | |
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN102727686A (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN1336219A (en) | Gynopathy treating traditional Chinese medicine | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN1899479A (en) | Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation | |
| CN101549105A (en) | Traditional Chinese medicine composition for treating migraine | |
| CN1939506A (en) | Vision-improving preparation with depressor, blood-sugar and blood-fat lowering functions and its making method | |
| CN101041037A (en) | Drug for curing diabetes and nephropathy and its preparing method | |
| CN102228648B (en) | Chinese medicinal composition for treating icterohepatitis | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN1943756A (en) | A Chinese traditional medicinal composite used for treatment of hypertension and its preparation method | |
| CN1285377C (en) | Gynecological inflammation treating medicine and its preparation method | |
| CN101468178A (en) | Medicament composition for treating fatty liver and preparation method thereof | |
| CN1943755B (en) | A Chinese traditional medicinal composition for treatment of hypertension and its preparation method | |
| CN1772270A (en) | Tiantan prepn for treating kidney-yang deficiency diseases and its production process | |
| CN1876148A (en) | A Chinese medicinal composition for replenishing kidney and strengthening bone and preparation method thereof | |
| CN1843460A (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1176702C (en) | Traditional Chinese medicine prepn. for treating Hepatitis | |
| CN103948875A (en) | Medicine for treating hepatitis B and preparation method thereof | |
| CN1116537A (en) | Traditional Chinese medicine composition for treating refractory headache | |
| CN1943682A (en) | A Chinese traditional medicinal composition for treatment of hepatitis C | |
| CN103070969A (en) | Chinese medicinal composition for reducing blood fat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG TAIYUAN CHINESE MEDICINE RESEARCH AND DEV Free format text: FORMER OWNER: ZHANG HUIYUN Effective date: 20091225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Shandong high tech Zone in Tai'an City, Phoenix Road South Patentee after: Shandong Taiyuan Chinese medicine research and Development Co.,Ltd. Address before: Dormitory two, Shandong University of Traditional Chinese Medicine, Lishan Mountain Road, Lixia District, Shandong, Ji'nan Patentee before: Zhang Huiyun |
|
| ASS | Succession or assignment of patent right |
Owner name: QINGDAO YANGGUANG HAICHUAN PHARMACEUTICAL TECHNOLO Free format text: FORMER OWNER: SHANDONG TAIYUAN TRADITIONAL CHINESE MEDICINE R + D CO., LTD. Effective date: 20101122 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 271000 SOUTH SECTION OF FENGTIAN ROAD, HIGH-TECH. ZONE, TAIAN CITY, SHANDONG PROVINCE TO: 266071 B20, NONGHAIYUAN, NO. 316, XIANGGANG EAST ROAD, LAOSHAN DISTRICT, QINGDAO CITY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101122 Address after: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee after: QINGDAO SUNSHINE HAICHUAN MEDICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 271000 Shandong high tech Zone in Tai'an City, Phoenix Road South Patentee before: Shandong Taiyuan Chinese medicine research and Development Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: QINGDAO HAICHUAN CENTER FOR INNOVATIVE BIOMEDICAL Free format text: FORMER OWNER: QINGDAO YANGGUANG HAICHUAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20130220 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130220 Address after: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee after: QINGDAO HAICHUAN INNOVATIVE BIOLOGY NATURAL RES CT Address before: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee before: Qingdao Sunshine Haichuan Medical Technology Development Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOP Free format text: FORMER OWNER: QINGDAO HAICHUAN CENTER FOR INNOVATIVE BIOMEDICAL RESEARCH Effective date: 20131224 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266071 QINGDAO, SHANDONG PROVINCE TO: 130012 CHANGCHUN, JILIN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131224 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee after: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. Address before: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee before: QINGDAO HAICHUAN INNOVATIVE BIOLOGY NATURAL RES CT |
|
| ASS | Succession or assignment of patent right |
Owner name: JINGYU TIANCHI PHARMACEUTICAL CO., LTD. Effective date: 20140304 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140304 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee after: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. Patentee after: Jingyu Tianchi Pharmaceutical Co.,Ltd. Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee before: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070502 |